Aeterna Zentaris Inc. (AEZS) (AEZS.TO) is all set to announce top-line results from its phase III study of Zoptrex in women with locally advanced, recurrent or metastatic endometrial cancer prior to the commencement of trading on Monday, May 1, 2017.
from RTT - Biotech http://ift.tt/2oUnOWJ
via IFTTT
No comments:
Post a Comment